Shim Jae-Hyuck, Lee Heung-Kyu, Chang Eun-Ju, Chae Wook-Jin, Han Jin-Hwan, Han Duck-Jong, Morio Tomohiro, Yang Jung-Jin, Bothwell Alfred, Lee Sang-Kyou
Department of Biotechnology, College of Engineering and Bioproducts Research Center, Yonsei University, Seoul, Korea.
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10617-22. doi: 10.1073/pnas.162522099. Epub 2002 Jul 29.
Tautomycetin (TMC) was identified as an immunosuppressor of activated T cells. Inhibition of T cell proliferation with TMC was observed at concentrations 100-fold lower than those needed to achieve maximal inhibition with cyclosporin A (CsA). TMC specifically blocked tyrosine phosphorylation of intracellular signal mediators downstream of Src tyrosine kinases in a T cell-specific manner, leading to apoptosis due to cleavage of Bcl-2, caspase-9, caspase-3, and poly(ADP-ribose) polymerase, but not caspase-1. In TMC-treated rats that received a heterotopic cardiac allograft, the graft survived more than 160 days, comparable to graft survival in allografted rats treated with CsA. Thus, TMC, whose mechanism of action is different from that of CsA or FK506, can be used as a potent T cell-specific immunosuppressor.
互隔交链孢酚(TMC)被鉴定为活化T细胞的免疫抑制剂。在比环孢素A(CsA)达到最大抑制所需浓度低100倍的浓度下,观察到TMC对T细胞增殖的抑制作用。TMC以T细胞特异性方式特异性阻断Src酪氨酸激酶下游细胞内信号介质的酪氨酸磷酸化,导致由于Bcl-2、半胱天冬酶-9、半胱天冬酶-3和聚(ADP-核糖)聚合酶的裂解而发生凋亡,但不包括半胱天冬酶-1。在接受异位心脏同种异体移植的TMC处理大鼠中,移植物存活超过160天,与用CsA处理的同种异体移植大鼠中的移植物存活情况相当。因此,作用机制不同于CsA或FK506的TMC可作为一种有效的T细胞特异性免疫抑制剂。